A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty
Phase 2
Recruiting
- Conditions
- Older Patients Undergoing Elective Total Hip Replacement
- Registration Number
- JPRN-jRCT2080221809
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Males with a female partner of childbearing potential should use contraception during the treatment period of the trial and up to 15 weeks after the last dose of investigational product
Females should be postmenopausal for at least 1 year at the time of screening
Elective total hip arthroplasty (eTHA) is scheduled
Have a body mass index of <40 kg/m2 and a weight <136.4 kg
Can climb at least 6 stairs with or without holding the handrail (but without human assistance), according to the patient at screening
Can stand up from a chair and walk more than 10 meters without human assistance
Take at least 12 seconds to perform the Timed Up and Go (TUG) test at screening
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method